Fukuda Denshi Co Ltd
TSE:6960
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.1), the stock would be worth ¥7 169.56 (25% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.4 | ¥9 610 |
0%
|
| 3-Year Average | 1.1 | ¥7 169.56 |
-25%
|
| 5-Year Average | 1 | ¥6 330.98 |
-34%
|
| Industry Average | 2 | ¥13 083.54 |
+36%
|
| Country Average | 1.4 | ¥9 395.64 |
-2%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Fukuda Denshi Co Ltd
TSE:6960
|
262.4B JPY | 1.4 | 14.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 9.6 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 3 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 5.6 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 2.2 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 3.8 | 31.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 2.2 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 4.7 | 45.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 28.1 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 1.7 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 5.1 | 21.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.4 |
| 70th Percentile | 2.1 |
| Max | 31 732 017.6 |
Other Multiples
Fukuda Denshi Co Ltd
Glance View
Fukuda Denshi Co Ltd. is a stalwart in the medical technology arena, having carved out a niche as a leading provider of innovative medical devices and systems. Founded in the mid-20th century, the company has stayed true to its mission of enhancing global healthcare with cutting-edge solutions. Over the years, Fukuda Denshi has evolved its product range to encompass a wide array of essential medical equipment, including electrocardiographs, patient monitoring systems, and ultrasonic diagnosis devices. These products are instrumental in hospitals and clinics for accurate patient diagnostics and monitoring, crucial for effective medical decision-making and improved patient outcomes. The company's journey from a modest operation to a global player is a testament to its commitment to research and development, enabling it to produce technologically advanced and reliable products. Fukuda Denshi's revenue model is primarily driven by the sales of its medical devices and systems across various healthcare settings globally. The company continually invests in innovation, ensuring that its products maintain a competitive edge in terms of functionality and reliability. By forming strategic alliances and partnerships, Fukuda Denshi expands its market reach and supports its distribution channels effectively. Additionally, the company provides comprehensive after-sales services, including maintenance and training, ensuring that healthcare providers can optimize the use of its devices. This service component not only enhances customer satisfaction but also establishes long-term relationships, contributing to recurring revenue streams and sustained business growth. Through a business model synergizing product excellence and strategic market engagement, Fukuda Denshi has solidified its position in the healthcare industry, meeting the growing demands for quality medical technology worldwide.